Surgery for Medullary Thyroid Cancer

  • Oliver Gimm


Medullary Thyroid Carcinoma Medullary Thyroid Medullary Thyroid Cancer Calcitonin Level Nodular Thyroid Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albores-Saavedra J, Monforte H, Nadji M, Morales AR (1988) C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol 19:795–799PubMedCrossRefGoogle Scholar
  2. 2.
    Bergholm U, Bergstrom R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132–138PubMedCrossRefGoogle Scholar
  3. 3.
    Bernier JJ, Rambaud JC, Cattan D, Prost A (1968) Medullary carcinoma of the thyroid associated with diarrhoea: report of five cases. Gut 9:726PubMedGoogle Scholar
  4. 4.
    Brauckhoff M, Gimm O, Brauckhoff K, Ukkat J, Thomusch O, Dralle H (2001) Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma. Langenbecks Arch Surg 386:434–439PubMedCrossRefGoogle Scholar
  5. 5.
    Cady B (1991) Papillary carcinoma of the thyroid. Semin Surg Oncol 7:81–86PubMedGoogle Scholar
  6. 6.
    Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284–7290PubMedGoogle Scholar
  7. 7.
    Casanova S, Rosenberg-Bourgin M, Farkas D, Calmettes C, Feingold N, Heshmati HM, Cohen R, Conte-Devolx B, Guillausseau PJ, Houdent C, et al (1993) Phaeochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases. Clin Endocrinol (Oxf) 38:531–537Google Scholar
  8. 8.
    Chan JK, Tse CC (1989) Solid cell nest-associated C-cells: another possible explanation for “C-cell hyperplasia” adjacent to follicular cell tumors. Hum Pathol 20:498–499PubMedCrossRefGoogle Scholar
  9. 9.
    Christensen SB, Ljungberg O, Tibblin S (1984) A clinical epidemiologic study of thyroid carcinoma in Malmo, Sweden. Curr Probl Cancer 8:1–49PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen MS, Hussain HB, Moley JF (2002) Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132:960–966; discussion 966–967PubMedCrossRefGoogle Scholar
  11. 11.
    Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM (2003) A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88:5438–5443PubMedCrossRefGoogle Scholar
  12. 12.
    Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M, Peacock ML (1996) Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 20:814–820; discussion 820–821PubMedCrossRefGoogle Scholar
  13. 13.
    de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786–794PubMedCrossRefGoogle Scholar
  14. 14.
    Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr (1993) Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 2:851–856PubMedCrossRefGoogle Scholar
  15. 15.
    Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565PubMedCrossRefGoogle Scholar
  16. 16.
    Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24:112–121PubMedCrossRefGoogle Scholar
  17. 17.
    Dralle H, Gimm O (1996) [Lymph node excision in thyroid carcinoma]. Chirurg 67:788–806PubMedCrossRefGoogle Scholar
  18. 18.
    Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Hoppner W (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744–750; discussion 750–751PubMedCrossRefGoogle Scholar
  19. 19.
    Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168PubMedCrossRefGoogle Scholar
  20. 20.
    Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BA, Mulligan LM (1996) The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579PubMedCrossRefGoogle Scholar
  21. 21.
    Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF, Evans DB (1999) Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230:697–707PubMedCrossRefGoogle Scholar
  22. 22.
    Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F (1995) Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 42:31–37Google Scholar
  23. 23.
    Froboese C (1923) Das aus markhaltigen Nervenfasern bestehende ganlienzellenlose echte Neurom in rankenform-zugleich ein Beitrag zu den nervösen Geschwulsten der Zunge und des Augenlides. Virchows Arch Pathol Anat 240:312–327Google Scholar
  24. 24.
    Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 122:1124–1130; discussion 1130–1131PubMedCrossRefGoogle Scholar
  25. 25.
    Gimm O, Ukkat J, Dralle H (1998) Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562–567; discussion 567–568PubMedCrossRefGoogle Scholar
  26. 26.
    Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H (2004) Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 28:1312–1316. Epub 2004 Nov 1304PubMedCrossRefGoogle Scholar
  27. 27.
    Girelli ME, Dotto S, Nacamulli D, Piccolo M, De Vido D, Russo T, Bernante P, Pelizzo MR, Busnardo B (1994) Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 80:113–117PubMedGoogle Scholar
  28. 28.
    Gomez JM, Biarnes J, Volpini V, Marti T (1998) Neuromas and prominent corneal nerves without MEN2B. Ann Endocrinol (Paris) 59:492–494Google Scholar
  29. 29.
    Gordon CM, Majzoub JA, Marsh DJ, Mulliken JB, Ponder BA, Robinson BG, Eng C (1998) Four cases of mucosal neuroma syndrome: multiple endocrine neoplasm 2B or not 2B? J Clin Endocrinol Metab 83:17–20PubMedCrossRefGoogle Scholar
  30. 30.
    Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–563PubMedCrossRefGoogle Scholar
  31. 31.
    Guyetant S, Wion-Barbot N, Rousselet MC, Franc B, Bigorgne JC, Saint-Andre JP (1994) C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Hum Pathol 25:514–521PubMedCrossRefGoogle Scholar
  32. 32.
    Hazard JB, Hawk WA, Crile G (1959) Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 19:152–161PubMedCrossRefGoogle Scholar
  33. 33.
    Henriksen JH, Schifter S, Moller S, Bendtsen F (2000) Increased circulating calcitonin in cirrhosis. Relation to severity of disease and calcitonin gene-related peptide. Metabolism 49:47–52PubMedCrossRefGoogle Scholar
  34. 34.
    Heshmati HM, Gharib H, van Heerden JA, Sizemore GW (1997) Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 103:60–69PubMedCrossRefGoogle Scholar
  35. 35.
    Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64–71PubMedCrossRefGoogle Scholar
  36. 36.
    Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH (1997) A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176–4178PubMedCrossRefGoogle Scholar
  37. 37.
    Hoie J, Jorgensen OG, Stenwig AE, Langmark F (1988) Medullary thyroid cancer in Norway. A 30-year experience. Acta Chir Scand 154:339–343PubMedGoogle Scholar
  38. 38.
    Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M (1997) Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung’s disease phenotype. Cancer Res 57:2870–2872PubMedGoogle Scholar
  39. 39.
    Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M (1999) Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18:3919–3922PubMedCrossRefGoogle Scholar
  40. 40.
    Jackson CE, Talpos GB, Kambouris A, Yott JB, Tashjian AH Jr, Block MA (1983) The clinical course after definitive operation for medullary thyroid carcinoma. Surgery 94:995–1001PubMedGoogle Scholar
  41. 41.
    Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO (2004) A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89:3521–3526PubMedCrossRefGoogle Scholar
  42. 42.
    Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF (2004) Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 89:4142–4145PubMedCrossRefGoogle Scholar
  43. 43.
    Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hufner M, Niederle B, Brabant G (2004) Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 112:52–58PubMedCrossRefGoogle Scholar
  44. 44.
    Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD (2001) Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 38:784–787PubMedCrossRefGoogle Scholar
  45. 45.
    Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–1148PubMedCrossRefGoogle Scholar
  46. 46.
    Kotzmann H, Schmidt A, Scheuba C, Kaserer K, Watschinger B, Soregi G, Niederle B, Vierhapper H (1999) Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid 9:943–947PubMedCrossRefGoogle Scholar
  47. 47.
    Lips CJM, Landsvater RM, Hoppener JWM, Geerdink RA, Blijham G, Jansen-Schillhorn van Veen JM, van Gils APG, de Witt MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, Ploos van Amstel HK, van Vroonhoven TJMV, Vroom TM (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828–835PubMedCrossRefGoogle Scholar
  48. 48.
    Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H (2001) Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104–1109PubMedCrossRefGoogle Scholar
  49. 49.
    Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H (2000) Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909–1915PubMedCrossRefGoogle Scholar
  50. 50.
    Machens A, Haedecke J, Holzhausen HJ, Thomusch O, Schneyer U, Dralle H (2000) Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbecks Arch Surg 385:398–401PubMedCrossRefGoogle Scholar
  51. 51.
    Machens A, Hinze R, Thomusch O, Dralle H (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28. Epub 2001 Nov 2022PubMedCrossRefGoogle Scholar
  52. 52.
    Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525PubMedCrossRefGoogle Scholar
  53. 53.
    Menko FH, van der Luijt RB, de Valk IA, Toorians AW, Sepers JM, van Diest PJ, Lips CJ (2002) Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 87:393–397PubMedCrossRefGoogle Scholar
  54. 54.
    Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F (2005) High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90:779–788. Epub 2004 Nov 2030PubMedCrossRefGoogle Scholar
  55. 55.
    Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K (1999) Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90:1–5PubMedGoogle Scholar
  56. 56.
    Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K (2002) Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26:1023–1028PubMedCrossRefGoogle Scholar
  57. 57.
    Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880–887; discussion 887–888PubMedCrossRefGoogle Scholar
  58. 58.
    Moley JF, Dilley WG, DeBenedetti MK (1997) Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 225:734–740; discussion 740–743PubMedCrossRefGoogle Scholar
  59. 59.
    Moley JF, Wells SA, Dilley WG, Tisell LE (1993) Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 114:1090–1095; discussion 1095–1096PubMedGoogle Scholar
  60. 60.
    Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ (1993) Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–460PubMedCrossRefGoogle Scholar
  61. 61.
    Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C (1999) Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation [letter]. JAMA 281:1587–1588PubMedCrossRefGoogle Scholar
  62. 62.
    Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A (1994) Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma [see comments]. J Clin Endocrinol Metab 78:826–829PubMedCrossRefGoogle Scholar
  63. 63.
    Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:1537–1542PubMedCrossRefGoogle Scholar
  64. 64.
    Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple P, Easton DF (1988) Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1:397–401PubMedCrossRefGoogle Scholar
  65. 65.
    Pujol RM, Matias-Guiu X, Miralles J, Colomer A, de Moragas JM (1997) Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity? J Am Acad Dermatol 37:349–352PubMedGoogle Scholar
  66. 66.
    Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H, Hofer R, Ritter M, Seif F, Buhr H, et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest 71:7–12CrossRefGoogle Scholar
  67. 67.
    Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL, Fombeur JP (1995) Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules [see comments]. Clin Endocrinol (Oxf) 42:453–460Google Scholar
  68. 68.
    Robbins KT, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW (1991) Standardizing neck dissection terminology. Official report of the Academy’s Committee for Head and Neck Surgery and Oncology. Arch Otolaryngol Head Neck Surg 117:601–605PubMedGoogle Scholar
  69. 69.
    Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559–567; discussion 567–568PubMedCrossRefGoogle Scholar
  70. 70.
    Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070–2075PubMedCrossRefGoogle Scholar
  71. 71.
    Shannon KE, Gimm O, Hinze R, Dralle H, Eng C (1999) Germline V804M mutation in the RET proto-oncogene in two apparently sporadic cases of FMTC presenting in the seventh decade of life. J Endocr Genet 1:39–45Google Scholar
  72. 72.
    Sipple JH (1961) The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 31:163–166CrossRefGoogle Scholar
  73. 73.
    Smallridge RC, Bourne K, Pearson BW, Van Heerden JA, Carpenter PC, Young WF (2003) Cushing’s syndrome due to medullary thyroid carcinoma: diagnosis by proopiomelanocortin messenger ribonucleic acid in situ hybridization. J Clin Endocrinol Metab 88:4565–4568PubMedCrossRefGoogle Scholar
  74. 74.
    Steiner AL, Goodman AD, Powers SR (1968) Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing—s disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47:371–409PubMedCrossRefGoogle Scholar
  75. 75.
    Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581–588PubMedCrossRefGoogle Scholar
  76. 76.
    Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60–66PubMedGoogle Scholar
  77. 77.
    Tung WS, Vesely TM, Moley JF (1995) Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 118:1024–1029; discussion 1029–1030PubMedCrossRefGoogle Scholar
  78. 78.
    Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B (1997) Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 82:1589–1593PubMedCrossRefGoogle Scholar
  79. 79.
    Wagenmann A (1922) Multiple Neurome des Auges und der Zunge. Ber Dtsch Ophthalmol Ges 43:282–285Google Scholar
  80. 80.
    Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, et al (1994) Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237–247; discussion 247–250PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Oliver Gimm
    • 1
  1. 1.Department of General, Visceral and Vascular SurgeryUniversity of HalleHalleGermany

Personalised recommendations